Edgewise Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EWTX research report →
Range $36 – $85
Price Chart
About the company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy.
- CEO
- Kevin Koch
- IPO
- 2021
- Employees
- 133
- HQ
- Boulder, CO, US
Get TickerSpark's AI analysis on EWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.29B
- P/E
- 4.45
- Fwd P/E
- 4.44
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 2.75
- EV/EBITDA
- 3.74
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 130.43%
- ROIC
- -11.55%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,266,000+0.0%
- Op Income
- $-191,406,000
- Net Income
- $-167,795,000-25.4%
- EPS
- $-1.63-12.4%
- OCF Growth
- -31.9%
- FCF Growth
- -30.6%
- 52W High
- $48.78
- 52W Low
- $19.76
- 50D MA
- $41.23
- 200D MA
- $37.27
- Beta
- 0.28
- RSI (14)
- 46
- Avg Volume
- 1.53M
No earnings-call transcripts are available for EWTX yet.
- Free Float
- 76.8%
- Shares Outstanding
- 107.59M
- Float Shares
- 82.58M
of shares held by institutions
238 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Orbimed Advisors LLC | 15.52M | 0 |
| Paradigm Biocapital Advisors LP | 10.22M | ▲ 2.85M |
| Ra Capital Management, L.P. | 8.39M | ▼ 2.04M |
| Blackrock, Inc. | 7.27M | ▲ 667.89K |
| Jupiter Topco LLC | 6.08M | ▲ 6.08M |
| Janus Henderson Group Ltd. | 5.92M | ▲ 1.35M |
| Novo Holdings A/S | 5.35M | 0 |
| Vanguard Group Inc | 4.87M | ▲ 67.68K |
| Driehaus Capital Management LLC | 4.73M | ▲ 250.68K |
| Perceptive Advisors LLC | 4.37M | ▼ 50.00K |
| Vanguard Capital Management LLC | 3.93M | ▲ 70.05K |
| Baker Bros. Advisors LP | 3.70M | ▼ 2.87M |
Held by 267 ETFs
Biggest fund positions in EWTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Donovan Joanne M. | sell | 854 |
| Nov 10, 26 | Nofi Michael | other | 10,937 |
| Nov 10, 26 | Nofi Michael | other | 10,937 |
| Nov 10, 26 | Nofi Michael | sell | 4,442 |
| Oct 1, 26 | Fox Jonathan C | other | 308 |
| Aug 12, 26 | Nofi Michael | other | 48,750 |
| Aug 12, 26 | Donovan Joanne M. | other | 65,000 |
| Aug 12, 26 | Russell Alan J | other | 65,000 |
| Aug 12, 26 | MOORE JOHN R | other | 65,000 |
| Aug 12, 26 | Derakhshan Behrad | other | 100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EWTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on EWTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 9
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
prnewswire.com · Nov 5
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 4
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com · Nov 2
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
prnewswire.com · Oct 8
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com · Oct 1
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
seekingalpha.com · Sep 22
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
prnewswire.com · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
